ICN And Fresenius In Talks On Kursk Tie-Up
US company ICN Pharmaceuticals, which is undertaking an investmentprogram in partnership with the Russian pharmaceuticals enterprise Leksredstva of Kursk, is engaged in talks with the German pharmaceutical and medical technology company Fresenius, relating to a project to launch medical preparations for children, and renal dialysis preparations.
ICN has a 96% stake in the Kursk operation, in which it invested $1.4 million in 1996, followed by $600,000 so far this year. ICN has also supported Leksredstva's opening up of two Italian-made tableting production lines.
The first will be commissioned this fall, with the second line expected to go into operation in 1998. The Kursk pharmaceuticals plant was originally established to produce drug intermediates but production was later expanded to include finished drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze